Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367224 | 0.86 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL34475902 | 0.84 | CYP4F2 (0.39) | CYP4F2CYP4A11 | |
| SCHEMBL2472218 | 0.82 | CYP2C19 (0.36) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL25188768 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL34476313 | 0.78 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL2633828 | 0.78 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL25568370 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL25568372 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL10587246 | 0.76 | CYP2C19 (0.30) | — | |
| SCHEMBL1273304 | 0.75 | OPRM1 (0.36) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | CYP4F2 13/4885CYP4A11 186/4885ALDH1A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.